The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

SAN DIEGO — Patients with eosinophilic esophagitis face significant ... Gold additionally noted that autoimmune and allergic disease incidence and prevalence are growing, but these increases ...

Discover a Phase 3 trial that evaluated stapokibart as an additional therapy for adults with moderate-to-severe seasonal ...

The FDA has granted approval to GSK's Nucala as an add-on maintenance treatment for adult patients suffering from inadequately controlled COPD.

Allergic conjunctivitis is a collection of common conditions observed more frequently in industrialized countries. These diseases range in severity from mild – interfering with quality of life ...

As pollen peaks for the season, the U.S. Food and Drug Administration is warning that some popular allergy medications could cause a rare but severe itching side effect. The FDA said in a safety ...

Precautions are essential during the monsoon season. Dr. Sharma advises patients to avoid touching or rubbing their eyes, ...

Congestion and other allergy symptoms in the morning may be caused by pollen, dust mites, pet dander, or indoor mold. Vacuuming, dusting, and taking an antihistamine before bed, among many other ...